MetaCap

Sight Sciences Inc. (SGHT)

NASDAQ: SGHTHealth CareMedical/Dental InstrumentsUSD

10.18-0.44 (-4.14%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

SGHT stock chart

Technical analysis

Key statistics

All statistics
Market cap
$565.79M
EPS (TTM)
-$0.52
52-week range
3.38 – 11.60
Day range
9.97 – 10.84
Volume / Avg
369.61K / 313.51K
Beta
—

52-week range

$3.38$11.60

SGHT stock today

Sight Sciences (SGHT) closed at $10.18 on Nov 20, down 4.14% (-$0.44), versus the S&P 500's 3.70% decline. At this level, SGHT sits near the top of its 52-week range of $3.38 to $11.60: 12.2% below the high, set on Nov 12, 2026 and 201.4% above the low. SGHT is up 28.4% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 40.2%.

Sight Sciences has posted a net loss over the last twelve months (EPS of -$0.52), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Sight Sciences

Company profile

Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segments, Surgical Glaucoma and Dry Eye. It offers OMNI, a surgical system family of products, such as OMNI Ergo for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and OMNI EDGE, an implant-free and minimally invasive glaucoma surgery technology.

Industry
Medical/Dental Instruments
CEO
Mr. Paul Badawi
Headquarters
Menlo Park, CA
Employees
186
IPO year
2021

Financial highlights

Full financials

In fiscal 2025, Sight Sciences generated $77.4 million in revenue, down 3.1% from fiscal 2024, its first annual decline since 2024. Sight Sciences reported a net loss of $38.4 million, compared with a loss of $51.5 million a year earlier. Gross margin was 86.2% (up from 85.5%) and operating margin -48.0%.

Sight Sciences annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$77.36M$79.87M$81.06M$71.33M$48.96M
Growth-3.13%-1.47%+13.63%+45.70%+77.12%
Net income$-38.43M$-51.51M$-55.55M$-86.24M$-62.96M
EPS (diluted)$-0.74$-1.03$-1.14$-1.80$-2.36

Analyst forecast

Forecast

Consensus (8 analysts)

buy

Avg. price target

$12.25+20.33%

  • Strong buy 1
  • Buy 5
  • Hold 2
  • Sell 0
  • Strong sell 0

Target range

Low $10.00High $14.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$-0.12 vs $-0.12

SGHT news

All SGHT news

Sight Sciences peers

Health Care sector
SGHT peer companies
CompanyPrice% ChgMarket capCompare
TCMDTactile Systems Technology Inc.25.60-1.50%$573.48Mvs SGHT
RCELAvita Medical Inc.15.62-2.31%$494.96Mvs SGHT
DCTHDelcath Systems Inc.18.79-2.34%$653.67Mvs SGHT
CARLCarlsmed Inc.17.42+1.16%$477.38Mvs SGHT
BVSBioventus Inc. Class A9.88-0.70%$676.53Mvs SGHT
ANGOAngioDynamics Inc.10.81+0.46%$454.61Mvs SGHT
MDXGMiMedx Group Inc3.05-1.93%$445.07Mvs SGHT
SENSSenseonics Holdings Inc.8.02-9.94%$439.34Mvs SGHT

Indexes, lists and sector

Sight Sciences stock FAQ

What is Sight Sciences's stock price today?

SGHT last traded at $10.18 as of Nov 20, 4:00 PM EST, down 4.14% on the day. Prices are delayed at least 15 minutes.

Who is Sight Sciences's CEO?

Mr. Paul Badawi is the chief executive officer of Sight Sciences Inc., which has about 186 employees.

What is the SGHT 52-week high?

The 52-week high for SGHT is $11.60 and the 52-week low is $3.38. The stock is currently 12.2% below its high.

Compare SGHT